Replies to post #14371 on Rebus Holdings Inc (RBSH)

[MMMQA]

GROWTH OPPORTUNITY FOR LEADING PLAYERS: VERNALIS, LEWIS AND CLARK PHARMACEUTICALS, HEPTARES THERAPEUTICS, ADVINUS THERAPEUTICS


The Adenosine A2 Receptor Antagonist Market is witnessing growth due to the presence of large pool of patients and technological advancements. The increasing compliance for Adenosine A2 Receptor Antagonist industry and massive unexplored market in the emerging economies, such as India and China are creating opportunities for the growth of the global Adenosine A2 Receptor Antagonist market. The advanced research and development facilities by the key players are propelling the demand for improved and cost effective products; further fuelling the growth of the global market.

The intelligence in Adenosine A2 Receptor Antagonist Market report includes investigations based on the current scenarios, historical records, and future predictions. Conclude an accurate data of various aspects. It presents the 360° overview of the competitive landscape of the industries. Thus, helping the companies to understand the threats and challenges in front of the businesses

Acorda bought Biotie and its adenosine A2A receptor antagonist drug tozadenant (SYN115) in a $363 million deal at the beginning of 2016, after seeing positive mid-stage data.